Filtered By:
Cancer: Brain Cancers

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 2156 results found since Jan 2013.

The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms
Int J Mol Sci. 2023 Mar 28;24(7):6328. doi: 10.3390/ijms24076328.ABSTRACTNeuroinflammation is a critical factor in developing and progressing numerous brain diseases, including neurodegenerative diseases. Chronic or excessive neuroinflammation can lead to neurotoxicity, causing brain damage and contributing to the onset and progression of various brain diseases. Therefore, understanding neuroinflammation mechanisms and developing strategies to control them is crucial for treating brain diseases. Studies have shown that neuroinflammation plays a vital role in the progression of neurodegenerative diseases, such as Alzheimer'...
Source: Cancer Control - April 13, 2023 Category: Cancer & Oncology Authors: Ming-Chang Chiang Tsung-Yu Tsai Chieh-Ju Wang Source Type: research

Galangin as an inflammatory response modulator: An updated overview and therapeutic potential
Chem Biol Interact. 2023 Apr 10:110482. doi: 10.1016/j.cbi.2023.110482. Online ahead of print.ABSTRACTNumerous chronic diseases, such as cancer, diabetes, rheumatoid arthritis, cardiovascular disease, and gastrointestinal disorders, all have an inflammation-based etiology. In cellular and animal models of inflammation, flavonols were used to show potent anti-inflammatory activity. The flavonols enhanced the synthesis of the anti-inflammatory cytokines transforming growth factor and interleukin-10 (IL-10) and reduced the synthesis of the prostaglandins IL-6, tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE2),...
Source: Chemico-Biological Interactions - April 12, 2023 Category: Molecular Biology Authors: Riya Thapa Obaid Afzal Abdulmalik Saleh Alfawaz Altamimi Ahsas Goyal Waleed Hassan Almalki Sami I Alzarea Imran Kazmi Vikash Jakhmola Sachin Kumar Singh Kamal Dua Ritu Gilhotra Gaurav Gupta Source Type: research

Astrocytic Chitinase ‐3‐like Protein 1 in Neurological Diseases: Potential Roles and Future Perspectives
AbstractChitinase-3-like protein 1 (CHI3L1) is a secreted glycoprotein characterized by its ability to regulate multiple biological processes, such as the inflammatory response and gene transcriptional signaling activation. Abnormal CHI3L1 expression has been associated with multiple neurological disorders and serves as a biomarker for the early detection of several neurodegenerative diseases. Aberrant CHI3L1 expression is also reportedly associated with brain tumor migration and metastasis, as well as contributions to immune escape, playing important roles in brain tumor progression. CHI3L1 is synthesized and secreted mai...
Source: Journal of Neurochemistry - April 7, 2023 Category: Neuroscience Authors: Fei Li, An Liu, Minggao Zhao, Lanxin Luo Tags: REVIEW Source Type: research

How do brain cancer patients experience MRI exam follow-up?
Brain cancer patients who undergo repeated brain MRI exams for follow-up appea...Read more on AuntMinnie.comRelated Reading: Government, nonprofit hospitals aren't cheaper for brain MRI What role does MRI have to play in diagnosis of acute stroke? Can brain MRI exams of fighter jet pilots reveal space travel effects? MRI reveals link between obesity, poor pediatric brain health MRI markers show racial disparities in brain health
Source: AuntMinnie.com Headlines - April 3, 2023 Category: Radiology Source Type: news

Rev-erb α agonist SR9009 protects against cerebral ischemic injury through mechanisms involving Nrf2 pathway
Conclusion: Taken together, Rev-erbα activation by SR9009 protects against ischemic stroke damage, at least, partly through Nrf2 pathway.
Source: Frontiers in Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Source Type: research

Ineffective triggering in patients with acute brain injury undergoing invasive mechanical ventilation
Conclusion: Ineffective triggering was found very common in patients with acute brain injury, especially those receiving craniotomy for brain tumor. Low respiratory drive was independently associated with severe ineffective triggering at expiratory phase.PMID:36997326 | DOI:10.4187/respcare.10596
Source: Respiratory Care - March 30, 2023 Category: Respiratory Medicine Authors: Xu-Ying Luo Xuan He Yi-Min Zhou Jian-Fang Zhou Guang-Qiang Chen Hong-Liang Li Yan-Lin Yang Linlin Zhang Jian-Xin Zhou Source Type: research

Neuroimaging findings and neurological manifestations in hospitalized COVID-19 patients: Impact of cancer and ventilatory support status
This study suggests COVID-19 is associated with neurological manifestations that may be visible with brain imaging techniques such as MRI. In our COVID-19 cohort, there was no association between cancer status and neuroimaging findings. Future studies might include more prospectively enrolled systematically characterized patients, allowing for more rigorous statistical analysis.
Source: PLoS One - March 24, 2023 Category: Biomedical Science Authors: Lily McCarthy Source Type: research

Absence of susceptibility vessel sign and hyperdense vessel sign in patients with cancer-related stroke
ConclusionThe absence of SVS but not HVS could help to identify paraneoplastic hypercoagulability in stroke patients with active cancer and guide patient care.
Source: Frontiers in Neurology - March 20, 2023 Category: Neurology Source Type: research

The vascular gene Apold1 is dispensable for normal development but controls angiogenesis under pathological conditions
AbstractThe molecular mechanisms of angiogenesis have been intensely studied, but many genes that control endothelial behavior and fate still need to be described. Here, we characterize the role ofApold1 (Apolipoprotein L domain containing 1) in angiogenesis in vivo and in vitro. Single-cell analyses reveal that - across tissues - the expression ofApold1 is restricted to the vasculature and thatApold1 expression in endothelial cells (ECs) is highly sensitive to environmental factors. UsingApold1−/− mice, we find thatApold1 is dispensable for development and does not affect postnatal retinal angiogenesis nor alters the ...
Source: Angiogenesis - March 18, 2023 Category: Molecular Biology Source Type: research

New paradigms in purinergic receptor ligand discovery
Neuropharmacology. 2023 Mar 13:109503. doi: 10.1016/j.neuropharm.2023.109503. Online ahead of print.ABSTRACTThe discovery and clinical implementation of modulators of adenosine, P2Y and P2X receptors have progressed dramatically in ∼50 years since Burnstock's definition of purinergic signaling. Although most clinical trials of selective ligands (agonists and antagonists) of these nineteen receptors failed, there is a renewed impetus to redirect efforts to new disease conditions and the discovery of more selective or targeted compounds with potentially reduced side effects, such as biased GPCR agonists. The elucidation of...
Source: Neuropharmacology - March 15, 2023 Category: Drugs & Pharmacology Authors: Kenneth A Jacobson Balaram Pradhan Zhiwei Wen Asmita Pramanik Source Type: research

Muscone promotes functional recovery by facilitating microglia polarization into M2 phenotype through PPAR- γ pathway after ischemic stroke
Cell Immunol. 2023 Mar 5;386:104704. doi: 10.1016/j.cellimm.2023.104704. Online ahead of print.ABSTRACTExploring regimens to facilitate microglia transformation from M1 to M2 phenotype is a feasible strategy to suppress neuroinflammation, therefore reinforcing functional recovery after ischemic stroke. Muscone easily crosses the blood brain barrier (BBB) and distributes throughout the brain. Here, the results illustrated the administration of 8 mg/kg muscone promoted functional recovery through reducing the infarct volume by 2,3,5-triphenyltetrazolium chloride (TTC) staining after ischemic stroke in mice. Then, the express...
Source: Cellular Immunology - March 15, 2023 Category: Allergy & Immunology Authors: Fei Liu Liwei Cao Shejing Hu Hongxiang Ye Qiang Wu Le Wu Source Type: research

New paradigms in purinergic receptor ligand discovery
Neuropharmacology. 2023 Mar 13:109503. doi: 10.1016/j.neuropharm.2023.109503. Online ahead of print.ABSTRACTThe discovery and clinical implementation of modulators of adenosine, P2Y and P2X receptors have progressed dramatically in ∼50 years since Burnstock's definition of purinergic signaling. Although most clinical trials of selective ligands (agonists and antagonists) of these nineteen receptors failed, there is a renewed impetus to redirect efforts to new disease conditions and the discovery of more selective or targeted compounds with potentially reduced side effects, such as biased GPCR agonists. The elucidation of...
Source: Neuropharmacology - March 15, 2023 Category: Drugs & Pharmacology Authors: Kenneth A Jacobson Balaram Pradhan Zhiwei Wen Asmita Pramanik Source Type: research